Back to today’s briefing

Story perspectives

Pediatric Cancer Breakthrough: 97.5% Survival Rate Achieved

9/24/2025

48 10 Full Breakdown

Summary

Story summary

Blinatumomab in pediatric B-cell ALL yielded 3-year disease-free survival of 97.5% vs 90.2%.
Evelyn Sengelaub, 8, achieved remission with no side effects and remains cancer-free.
Funding concerns may slow trials; desmoid guidelines favor surveillance unless life or quality of life is threatened.
Nirogacestat shows 71% PFS improvement; Giredestrant plus everolimus improves PFS in ER-positive breast cancer, with regulatory submission planned.

1 of 1

Story summary

Blinatumomab in pediatric B-cell ALL yielded 3-year disease-free survival of 97.5% vs 90.2%.
Evelyn Sengelaub, 8, achieved remission with no side effects and remains cancer-free.
Funding concerns may slow trials; desmoid guidelines favor surveillance unless life or quality of life is threatened.
Nirogacestat shows 71% PFS improvement; Giredestrant plus everolimus improves PFS in ER-positive breast cancer, with regulatory submission planned.